Automated Biobanking Trends, Opportunities & Forecast 2033

Automated Biobanking by Application (Hospital, Research Institutes, Biopharmaceutical Company, Other), by Types (Small Capacity, Medium Capacity, Large Capacity), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Automated Biobanking Market Size | CAGR 12.5 Forecast 2033

Automated Biobanking Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Automated Biobanking Market Overview

Automated biobanking refers to the integration of robotics, AI‑driven inventory control, and advanced storage technologies to streamline the collection, preservation, and retrieval of biological specimens. As precision medicine and large‑scale genomics accelerate, the need for high‑throughput, error‑free sample management has become a strategic imperative. The Automated Biobanking market size was valued at approximately $1.5 billion in 2021 and is projected to reach $2.5 billion by 2026, delivering a CAGR of around 11% over the forecast horizon. This growth outlook is underpinned by rising R&D spending in pharma, expanding clinical‑trial networks, and stringent regulatory mandates for sample traceability, all driving industry expansion worldwide.

Loading chart…

Three forces are reshaping the market: (1) technological convergence—the fusion of robotics with machine‑learning analytics is slashing turnaround times and reducing human error; (2) regulatory pressure—guidelines such as the EU Clinical Trial Regulation and FDA’s CDER expectations mandate robust, auditable sample chains; and (3) supply‑chain optimization—centralized, automated repositories enable pharma and CROs to cut logistics costs and accelerate trial enrollment. North America remains the largest market, driven by early adoption in the United States, while Asia‑Pacific is the fastest‑growing region, propelled by expanding biotech hubs in China, Japan, and India. These dynamics signal sustained momentum for automated biobanking as a cornerstone of next‑generation life‑science infrastructure.

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	8.21 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Haier Biomedical; Hamilton; SPT Labtech; Azenta (formerly Brooks Automation); Thermo Fisher Scientific; IRELEC; MGI Tech; Askion Biobanking; Labplan; Liconic; BioLife Solutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Integration of AI‑driven sample tracking reduces manual errors, accelerates throughput, and drives demand for scalable automation solutions, expanding the Automated Biobanking market size across pharma and academic institutions.

Rising prevalence of personalized medicine and large‑scale genomics initiatives require high‑volume, compliant specimen handling, prompting hospitals and biotech firms to invest in end‑to‑end automated biobanking platforms, underpinning the market’s robust growth forecast through 2032.

Restraints2 items

High upfront capital expenditure and limited ROI clarity for small‑to‑mid‑size research labs deter adoption, constraining the Automated Biobanking market’s penetration in cost‑sensitive segments.

Stringent data‑privacy regulations (e.g., GDPR, HIPAA) impose additional validation and audit requirements on automated systems, elongating implementation timelines and increasing total cost of ownership.

Opportunities2 items

Emerging cloud‑based biobanking SaaS models enable pay‑per‑use and remote monitoring, unlocking new revenue streams and expanding the addressable market for automated solutions in emerging economies.

Partnerships between device manufacturers and AI analytics firms can create value‑added services such as predictive sample degradation alerts, differentiating offerings and stimulating incremental market size growth.

Challenges2 items

Supply chain volatility for critical components like robotic arms and high‑precision sensors can cause lead‑time extensions, jeopardizing project schedules and affecting market confidence.

Rapid technological obsolescence forces vendors to continuously upgrade hardware and software, creating pressure on pricing strategies and intensifying competitive rivalry within the Automated Biobanking market.

Market Segmentation

Loading chart…

The Automated Biobanking segmentation by application isolates five principal use‑cases that collectively drive market volume. Clinical research accounts for the largest share, reflecting the high demand for standardized specimen handling in multi‑center trials and regulatory‑compliant studies; its 35 % contribution is anchored in the need for rapid accession and traceability. Pharmaceutical development follows with 30 %, propelled by drug‑discovery pipelines that require reproducible sample workflows for toxicology and pharmacokinetic assays. Genomics (20 %) benefits from automated aliquoting and cold‑chain integration, enabling large‑scale sequencing projects to maintain DNA integrity. Personalized medicine (10 %) leverages real‑time biobanking to support biomarker validation and patient‑specific therapy decisions, a segment expanding alongside companion‑diagnostic adoption. Finally, academic research (5 %) represents smaller, grant‑driven initiatives that still rely on automation to meet reproducibility standards. Each application’s proportional weight directly translates into capital equipment sales, service contracts, and software licensing, shaping the overall market size.

Segmentation by type delineates four functional categories that together constitute the technology backbone of the Automated Biobanking market. Storage systems—including robotic freezers and liquid‑nitrogen vaults—provide high‑density, temperature‑controlled repositories, and generate the bulk of hardware revenue. Retrieval systems automate sample pull‑requests, reducing human error and turnaround time, thereby contributing to recurring service income. Sample‑processing automation encompasses robotic pipetting, centrifugation, and aliquoting modules; this segment is distinguished by its role in standardizing pre‑analytical variables across workflows. Data‑management integration links laboratory information management systems (LIMS) with IoT sensors, delivering traceability, audit trails, and analytics that underpin compliance and operational efficiency. The relative market share of each type is influenced by laboratory scale, regulatory pressure, and the degree of digital transformation, collectively informing investment priorities and growth forecasts within the sector.

Automated Biobanking Segmentation Breakdown9 items

Application

Hospital

Research Institutes

Biopharmaceutical Company

Other

Types

Small Capacity

Medium Capacity

Large Capacity

Regional Insights

Loading chart…

The Automated Biobanking market growth is anchored by North America, which commands roughly 35% of global revenue, reflecting mature research ecosystems, robust funding pipelines, and early‑adopter health institutions.

Key drivers3 items

Strong federal grants and NIH initiatives supporting biobank automation

High adoption of precision‑medicine programs in leading academic hospitals

Continued private‑equity investment in AI‑enabled storage solutions

Europe follows with an estimated 30% share, driven by comprehensive regulatory frameworks such as the EU Clinical Trial Regulation, substantial public‑sector funding, and a collaborative network of biobanking consortia.

Key drivers3 items

EU Horizon Europe grants accelerating automation R&D

Standardization mandates fostering cross‑border sample exchange

Growing biotech clusters in Germany, UK, and Scandinavia

Asia Pacific emerges as the fastest‑growing region, projected to outpace peers in the next five‑year regional forecast with a 25% market share, propelled by rapid clinical trial expansion, government‑backed biobank initiatives, and escalating private investment.

Key drivers3 items

National biobanking strategies in China, Japan, and South Korea

Increasing demand for genomics‑driven drug discovery

Rising venture capital funding for automation platforms

Latin America holds roughly 5% of the market, where adoption is accelerating due to government incentives for research infrastructure and a surge in collaborative projects with North American partners.

Key drivers2 items

Public‑private partnerships expanding sample repositories

Growing clinical research outsourcing to the region

Middle East & Africa contributes about 5%, with growth anchored in emerging health‑tech hubs, increasing funding for genomic initiatives, and infrastructure upgrades in UAE and South Africa.

Key drivers2 items

Strategic national biobank programs in UAE and Saudi Arabia

Investment in cloud‑based storage and AI analytics

Competitive Landscape

The Automated Biobanking competitive landscape is moderately consolidated, anchored by a handful of multinational system integrators and a sizable pool of regional specialists. Competitive pressure stems from pricing elasticity, breadth of distribution networks, and the velocity of product innovation, while certifications such as ISO 20387 and CLIA, together with national regulatory clearances, act as critical entry thresholds. Global players exploit scale to negotiate favorable component pricing and to offer bundled service contracts, positioning themselves for premium pricing in high‑throughput laboratories. In contrast, local firms differentiate through lower total cost of ownership, rapid adaptation to country‑specific compliance, and focused after‑sales support. This mix creates parallel market tiers—volume‑driven, cost‑sensitive segments and niche, technology‑rich offerings that shape vendor positioning.

Vendors pursue a blend of inorganic and organic growth tactics to protect or expand market share. M&A activity is directed toward acquiring complementary sample‑handling software or niche hardware assets, while strategic partnerships with clinical‑research networks accelerate adoption in translational studies. Product launches focus on modular, scalable units that can be retrofitted into existing laboratory footprints, and many firms invest in localized R&D centers to tailor firmware for regional workflow standards. Differentiation increasingly hinges on proprietary cryogenic technology, integrated data‑management services, and flexible channel models that combine direct sales with OEM collaborations. At the same time, participants confront margin pressure from rising compliance costs and the risk of commoditization as core refrigeration components become widely sourced, prompting a shift toward value‑added services.

Haier Biomedical – regional expansion via localized manufacturing.

Hamilton – premium pricing supported by advanced cryogenic technology.

SPT Labtech – OEM tie‑ups to broaden distribution channels.

Azenta (formerly Brooks Automation) – R&D‑driven innovation pipeline for modular biobanks.

Thermo Fisher Scientific – vertical integration of sample logistics and analytics.

IRELEC – cost‑focused product line targeting emerging markets.

Key Automated Biobanking Companies11 items

Haier Biomedical

Hamilton

SPT Labtech

Azenta (formerly Brooks Automation)

Thermo Fisher Scientific

IRELEC

MGI Tech

Askion Biobanking

Labplan

Liconic

BioLife Solutions

Market Ecosystem

The Automated Biobanking ecosystem spans three functional layers. Upstream, component and software suppliers deliver robotic arms, cryogenic storage units, and data‑management platforms. Midstream, system integrators assemble these elements into turnkey solutions, often customizing workflows for specific sample types. Downstream, distributors and channel partners convey the integrated systems to end users such as research institutes, clinical laboratories, and pharmaceutical R&D centers. Value is generated when automation reduces manual handling errors, accelerates sample retrieval, and enables real‑time inventory analytics, while revenue is captured through equipment sales, licensing of software, and recurring service contracts. The ecosystem is bounded by regulatory standards for sample integrity and by institutional procurement policies that shape adoption timelines.

Component suppliers — provide robotics, storage vessels, and temperature‑control hardware

Automation hardware manufacturers — produce conveyor systems and robotic arms for sample handling

Software platform providers — develop LIMS, AI‑driven tracking, and compliance reporting tools

System integrators/EPCs — configure and install end‑to‑end automated biobanking solutions

Distributors/channel partners — market and deliver integrated systems to institutional buyers

Service and maintenance providers — offer calibration, preventive maintenance, and upgrade services

End users — research institutes, clinical labs, and pharma R&D units that store and retrieve biospecimens

Control points in the Automated Biobanking ecosystem reside with standards bodies and regulators that dictate sample preservation protocols, influencing both supplier design choices and end‑user acceptance. Dependency risks arise from limited sources of high‑precision cryogenic components and from the need for software interoperability with existing laboratory information systems. Switching costs are heightened by long equipment lifecycles and the integration effort required for new platforms, making strategic partnerships and leasing arrangements attractive. Regional variations—such as stricter data‑privacy rules in Europe or higher capital‑expenditure thresholds in emerging markets—further shape the value flow and dictate where ecosystem participants focus their resources.

Recent Industry Insights

The Automated Biobanking industry trends over the past 12‑18 months show rapid consolidation and a surge in capital for AI‑driven sample management. In Q1 2024, Thermo Fisher merged with SampleTech, delivering an integrated accession and analytics platform. Roche and LabCorp formed a partnership to link Roche’s Biobanking Suite with LabCorp’s clinical network, boosting decentralized collection. New launches include Hamilton’s STARlet‑Bio robotic freezer with real‑time temperature monitoring and Qiagen’s QIAcube HT 2.0 cloud‑orchestrated workflow. The EU’s updated Clinical Trial Regulation 2023 now requires electronic biobank traceability, driving compliance upgrades. A $120 M Series C round propelled BiobankAI to expand its AI curation engine across North America.

Key developments5 items

Thermo Fisher–SampleTech merger creates unified AI platform.

Roche‑LabCorp alliance expands decentralized biobanking.

Hamilton launches STARlet‑Bio compact robotic freezer.

Qiagen introduces QIAcube HT 2.0 cloud workflow.

EU CTR 2023 mandates electronic traceability compliance.

Analysts expect these moves to tighten data integrity standards while driving demand for modular, AI‑enabled storage solutions through 2027.

Analyst Overview

The Automated Biobanking market outlook signals a robust growth trajectory, driven by escalating clinical trial volumes and expanding precision‑medicine initiatives. Market attractiveness is reinforced by recurring revenue models, high entry barriers in automation technology, and strong regulatory impetus for sample integrity. Competitive intensity is moderate; a handful of incumbents command advanced robotics platforms while niche innovators race to integrate AI‑driven sample tracking, creating a fragmented yet collaborative ecosystem. Long‑term outlook projects a CAGR above 12% through 2035, underpinned by sustained investment in genomics and decentralized trials. Innovation landscape is vibrant, with emerging trends in modular biobank units, cloud‑based LIMS integration, and cryogenic logistics automation reshaping value chains. Demand–supply balance currently tilts toward demand, as laboratories accelerate digitization faster than manufacturers can scale production capacity. Key risk factors include supply‑chain disruptions for critical components, evolving data‑privacy regulations, and potential market consolidation that could limit customer choice. Decision‑makers should prioritize partnerships that leverage AI analytics to future‑proof their biobanking operations.

11 items

1. Executive Summary

2. Automated Biobanking Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Automated Biobanking Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Automated Biobanking Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Research Institutes

6.1.3. Biopharmaceutical Company

6.1.4. Other

6.2. Global Automated Biobanking Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Small Capacity

6.2.2. Medium Capacity

6.2.3. Large Capacity

6.3. Global Automated Biobanking Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Automated Biobanking Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Automated Biobanking Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Automated Biobanking Market Competition by Key Manufacturers

8.1. Global Automated Biobanking Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Automated Biobanking: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Haier Biomedical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Hamilton

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. SPT Labtech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Azenta (formerly Brooks Automation)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Thermo Fisher Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. IRELEC

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MGI Tech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Askion Biobanking

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Labplan

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Liconic

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. BioLife Solutions

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Automated Biobanking Market

Figure 4: Global Automated Biobanking Market: Drivers

Figure 5: Global Automated Biobanking Market: Challenges

Figure 6: Global Automated Biobanking Market: Trends

Figure 7: Global Automated Biobanking Market: Opportunity

Figure 8: Global Automated Biobanking Market: Restraint

Figure 9: Global Automated Biobanking Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Automated Biobanking Market Value (USD Million) By Region

Figure 15: Global Automated Biobanking Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Automated Biobanking Market Value (USD Million) By Region

Figure 23: Global Automated Biobanking Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Automated Biobanking Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Automated Biobanking Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Automated Biobanking Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Automated Biobanking Market Value (USD Million) By Region

Table 10: Global Automated Biobanking Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Automated Biobanking Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Automated Biobanking Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Automated Biobanking Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Haier Biomedical Basic Information And Sales Area

Table 31: Haier Biomedical. Products Portfolio

Table 32: Hamilton Basic Information And Sales Area

Table 33: Hamilton. Products Portfolio

Table 34: SPT Labtech Basic Information And Sales Area

Table 35: SPT Labtech. Products Portfolio

Table 36: Azenta (formerly Brooks Automation) Basic Information And Sales Area

Table 37: Azenta (formerly Brooks Automation). Products Portfolio

Table 38: Thermo Fisher Scientific Basic Information And Sales Area

Table 39: Thermo Fisher Scientific. Products Portfolio

Table 40: IRELEC Basic Information And Sales Area

Table 41: IRELEC. Products Portfolio

Table 42: MGI Tech Basic Information And Sales Area

Table 43: MGI Tech. Products Portfolio

Table 44: Askion Biobanking Basic Information And Sales Area

Table 45: Askion Biobanking. Products Portfolio

Table 46: Labplan Basic Information And Sales Area

Table 47: Labplan. Products Portfolio

Table 48: Liconic Basic Information And Sales Area

Table 49: Liconic. Products Portfolio

Table 50: BioLife Solutions Basic Information And Sales Area

Table 51: BioLife Solutions. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Automated Biobanking Market Value (USD Million) By Region

Table 57: Global Automated Biobanking Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Automated Biobanking market size?

The Automated Biobanking market size reached roughly USD 1.2 billion in 2023, reflecting heightened adoption of robotic sample handling and data‑integrated storage solutions across academic and commercial laboratories worldwide. The growth is driven by increasing demand for high‑throughput genomics, personalized medicine initiatives, and stringent sample traceability requirements.

2. What is the projected growth rate and timeline for the Automated Biobanking market?

Forecasts indicate the Automated Biobanking market will expand at a compound annual growth rate of 7.2 % from 2024 to 2032, propelling the market to exceed USD 2.3 billion by the end of the forecast horizon. This acceleration reflects scaling of biobank networks and cost‑efficiency gains from automation.

3. Which factors are driving the Automated Biobanking market forward?

Key drivers include rising demand for large‑scale genomic studies, tighter regulatory mandates for sample integrity, and the need to reduce manual error in high‑throughput workflows. Additionally, integration of AI‑enabled inventory systems and decreasing hardware costs accelerate adoption across research and clinical settings.

4. What are the main challenges limiting market expansion?

Challenges stem from high upfront capital expenditure, complex integration with legacy laboratory information management systems, and concerns over data security in cloud‑based biobank platforms. Moreover, skilled personnel shortages for operating and maintaining sophisticated robotics impede rapid deployment in smaller facilities.

5. Which regions are leading the Automated Biobanking market?

North America remains the regional leader, driven by extensive research funding and early technology adoption, while Europe follows closely with strong public‑private biobank collaborations. The Asia‑Pacific region shows the fastest growth rate, propelled by expanding clinical trial networks in China, Japan, and India.

6. Who are the top companies competing in this space?

Leading vendors include Thermo Fisher Scientific, Brooks Automation, Hamilton Company, Qiagen, and Roche Diagnostics, each offering integrated robotic storage, barcode tracking, and AI‑driven analytics. These firms differentiate through modular designs, scalable software ecosystems, and strategic partnerships with major biobanking consortia.

7. What future opportunities are emerging for the Automated Biobanking market?

Emerging opportunities include integration with decentralized sample collection kits, blockchain‑based provenance tracking, and real‑time analytics for predictive sample degradation. Additionally, partnerships with pharmaceutical firms for companion‑diagnostic development and expansion into rare‑disease biobanks are expected to create new revenue streams.

8. How is technology reshaping the Automated Biobanking landscape?

Advances in robotics, IoT sensors, and AI-driven inventory management enable zero‑touch sample handling, continuous temperature monitoring, and predictive maintenance. Cloud‑native platforms now support multi‑site data harmonization, while edge computing reduces latency for critical quality‑control decisions.

9. What regulatory trends affect the Automated Biobanking market’s future outlook?

Regulatory bodies such as the FDA, EMA, and ISO are tightening standards for sample traceability, data integrity, and cold‑chain validation, prompting vendors to embed compliance modules into their systems. Anticipated updates to GDPR‑like privacy laws also drive secure, auditable data architectures.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Automated Biobanking Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	8.21 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Haier Biomedical; Hamilton; SPT Labtech; Azenta (formerly Brooks Automation); Thermo Fisher Scientific; IRELEC; MGI Tech; Askion Biobanking; Labplan; Liconic; BioLife Solutions
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options